Literature DB >> 22313996

Complications following prostate needle biopsy requiring hospital admission or emergency department visits - experience from 1000 consecutive cases.

G Igor Pinkhasov1, Yu-Kuan Lin, Ricardo Palmerola, Paul Smith, Frank Mahon, Matthew G Kaag, J Edward Dagen, Lewis E Harpster, Carl T Reese, Jay D Raman.   

Abstract

OBJECTIVE: • To review a contemporary cohort of patients undergoing a transrectal ultrasound-guided prostate needle biopsy (TRUS PNBx) at a single centre to determine the incidence of major complications necessitating hospital admission or emergency department (ED) visits. PATIENTS AND METHODS: • The charts of 1000 consecutive patients undergoing TRUS PNBx were reviewed. • All patients received peri-procedural antibiotic prophylaxis with either ciprofloxacin or co-trimoxazole. • Hospital admission and ED visits within 30 days of the procedure were identified for indication, management and outcome. • Patient comorbidities and biopsy characteristics were reviewed for association with complications.
RESULTS: • Of the 1000 patients, 25 (2.5%) had post-biopsy complications requiring hospital admission or an ED visit. • Indications included twelve patients (1.2%) with urosepsis, eight (0.8%) with acute urinary retention requiring urethral catheterization, four (0.4%) with gross haematuria requiring bladder irrigation for <24 h, and one (0.1%) with a transient ischaemia attack 1 day after biopsy. • Patients with urosepsis had an average hospitalization of 5 days, and 75% carried quinolone-resistant Escherichia coli organisms. • All patients with urinary retention had catheters removed within 10 days. No patients with haematuria required a blood transfusion. • No demographic or biopsy variables were particularly associated with development of a post-procedure complication.
CONCLUSIONS: • In this large contemporary series of TRUS PNBx, we observed a 2.5% rate of major complications requiring hospital admission or an ED visit. • No clinical or biopsy variables were directly associated with development of complications. • These data may be valuable when counselling patients before biopsy.
© 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22313996     DOI: 10.1111/j.1464-410X.2011.10926.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  36 in total

Review 1.  Prevention and treatment of biopsy-related complications.

Authors:  Ramgopal Satyanarayana; Dipen Parekh
Journal:  Curr Urol Rep       Date:  2014-02       Impact factor: 3.092

2.  One-Stop MRI and MRI/transrectal ultrasound fusion-guided biopsy: an expedited pathway for prostate cancer diagnosis.

Authors:  Alessandro Tafuri; Akbar N Ashrafi; Suzanne Palmer; Aliasger Shakir; Giovanni E Cacciamani; Atsuko Iwata; Tsuyoshi Iwata; Jie Cai; Akash Sali; Chhavi Gupta; Luis G Medina; Mariana C Stern; Vinay Duddalwar; Manju Aron; Inderbir S Gill; Andre Abreu
Journal:  World J Urol       Date:  2019-06-07       Impact factor: 4.226

3.  Population-based linkage of health records to detect urological complications and hospitalisation following transrectal ultrasound-guided biopsies in men suspected of prostate cancer.

Authors:  Dinesh Ganeswaran; Clare Sweeney; Fahad Yousif; S Lang; C Goodman; Ghulam Nabi
Journal:  World J Urol       Date:  2012-06-27       Impact factor: 4.226

4.  Does metabolic syndrome increase the risk of infective complications after prostate biopsy? A critical evaluation.

Authors:  Cahit Sahin; Bilal Eryildirim; A Cihangir Cetinel; Gokhan Faydaci; Fehmi Narter; Cemal Goktas; Kemal Sarica
Journal:  Int Urol Nephrol       Date:  2015-01-15       Impact factor: 2.370

5.  Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial.

Authors:  Paul F Pinsky; Howard L Parnes; Gerald Andriole
Journal:  BJU Int       Date:  2013-11-21       Impact factor: 5.588

6.  Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score.

Authors:  Donna P Ankerst; Cathee Till; Andreas Boeck; Phyllis J Goodman; Catherine M Tangen; Ian M Thompson
Journal:  Urology       Date:  2013-09-20       Impact factor: 2.649

7.  First report of robot-assisted transperineal fusion versus off-target biopsy in patients undergoing repeat prostate biopsy.

Authors:  S Kaufmann; J Mischinger; B Amend; S Rausch; M Adam; M Scharpf; F Fend; U Kramer; M Notohamiprodjo; K Nikolaou; A Stenzl; J Bedke; S Kruck
Journal:  World J Urol       Date:  2016-11-15       Impact factor: 4.226

8.  Intraprostatic hematoma with active bleeding post-prostate biopsy.

Authors:  Lan Qian Lancia Guo; Benny Chi-Bun So; David Sadler; Robin R Gray
Journal:  Can Urol Assoc J       Date:  2014-11       Impact factor: 1.862

9.  Erectile dysfunction in 1050 men following extended (18 cores) vs saturation (28 cores) vs saturation plus MRI-targeted prostate biopsy (32 cores).

Authors:  P Pepe; M Pennisi
Journal:  Int J Impot Res       Date:  2015-08-20       Impact factor: 2.896

10.  Active surveillance for the management of localized prostate cancer: Guideline recommendations.

Authors:  Chris Morash; Rovena Tey; Chika Agbassi; Laurence Klotz; Tom McGowan; John Srigley; Andrew Evans
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.